IDEXX Laboratories stock (US45167R1041): Shares fall 5% despite beating earnings estimates

IDEXX Laboratories shares dropped 5.0% on May 11, 2026, even as the veterinary diagnostics leader reported first-quarter earnings of $3.47 per share, beating analyst consensus by $0.06.

IDEXX Laboratories Inc reported stronger-than-expected quarterly results, yet shares fell 5.0% to $532.00 on May 11, 2026, according to GuruFocus as of May 11, 2026. The company posted earnings per share of $3.47 versus analyst estimates of $3.41 and revenue of $1.14 billion, according to MarketBeat as of May 12, 2026. Despite the earnings beat, the stock decline reflects broader market volatility and investor caution around the company's forward guidance.

As of: May 12, 2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: IDEXX Laboratories Inc
• Sector/industry: Veterinary diagnostics and software
• Headquarters/country: Westbrook, Maine, United States
• Core markets: Companion animal diagnostics, water testing, livestock diagnostics
• Key revenue drivers: Diagnostic instruments, consumables, software solutions
• Home exchange/listing venue: NASDAQ (IDXX)
• Trading currency: USD

IDEXX Laboratories: core business model

IDEXX Laboratories is a global leader in veterinary diagnostics, developing advanced diagnostic instruments, consumables, and software for companion animal, livestock, and water testing markets. The company's core strength lies in its proprietary diagnostic platforms, which veterinarians use to detect diseases in animals. IDEXX also develops cancer detection tests for animals, including blood-based screening that can help detect cancers like lymphoma early, often months before symptoms appear, according to InsiderMonkey as of May 2026. The company operates in over 175 countries and serves veterinary clinics, diagnostic laboratories, and water utilities.

Main revenue and product drivers for IDEXX Laboratories

IDEXX's revenue is driven by recurring consumables sales tied to its installed base of diagnostic instruments, software subscriptions, and new product launches. The company raised its fiscal 2026 outlook, projecting reported revenue growth of 8.6% to 10.6%, according to InsiderMonkey as of May 2026. However, Bank of America noted slower InVue installations as a potential headwind, suggesting near-term pressure on instrument placements despite strong consumables demand.

Valuation and analyst sentiment

At $532.00 on May 11, 2026, IDEXX shares traded at a 14.8% discount to GuruFocus's estimated fair value of $624.56, according to GuruFocus as of May 11, 2026. The stock carries a GF Score of 99 out of 100, indicating strong fundamentals. Analysts rate the stock a Moderate Buy with an average price target of $751, according to MarketBeat as of May 12, 2026. The recent share decline may present a margin of safety for long-term investors, though near-term volatility remains a consideration.

Conclusion

IDEXX Laboratories delivered a solid earnings beat in its latest quarter, yet the 5% share decline underscores investor focus on execution risks and near-term headwinds in instrument placements. The company's raised fiscal 2026 guidance and strong diagnostic fundamentals support long-term growth, but market sentiment remains cautious. At current valuations, the stock offers potential appeal for investors with a multi-year horizon, though near-term volatility should be expected.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.